[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Fourth Affiliated Hospital of Zhejiang University School of Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":596},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,65,0,25,[9,48,78,108,142,167,191,210,227,245,269,291,310,339,358,383,404,432,453,472,491,514,533,550,576],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100650837","research-and-application-of-an-ai-agent-based-mbbs-course-assistant-100650837",false,"NCT07752160","Research and Application of an AI Agent-Based MBBS Course Assistant","Inclusion Criteria:\n\n* 1: The undergraduate students of the \"Belt and Road Initiative\" International Medical School of Zhejiang University who have officially registered for the MBBS program\n* 2: Voluntary signing of the informed consent form\n\nExclusion Criteria:\n\n* 1: Having severe mental illnesses (such as severe depression, bipolar disorder, acute phase of schizophrenia), serious physical diseases or cognitive impairments\n* 2: Is currently participating in other studies that may affect the outcome indicators of this research\n* 3: Have systematically studied or participated in research that is highly similar to this study\n* 4: No experience of AI agent learning",true,"ALL","16 Years","25 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Prior to the quasi-experiment, this study performed semi-structured interviews among Bachelor of Medicine and Bachelor of Surgery(MBBS) undergraduate students from the Belt and Road International Medical College, Zhejiang University. Based on learning science, cognitive load theory and causal inference frameworks, the interview outline focused on system usability, feedback quality, learning reasoning processes, cognitive burden and instructional optimization advice. Each 20-30 minute individual interview was audio-recorded with participants' informed consent and verbatim transcribed for standardized qualitative analysis.\n\nThe quasi-experiment recruited no fewer than 60 MBBS students. The sample size was determined by intergroup statistical power analysis to guarantee around 30 participants per group for valid intergroup comparison. All eligible students were randomly assigned into two groups with balanced demographic and academic baseline characteristics. The experimental group (n=30) received structured epidemiological learning assisted by the (Socratic Agent for Guided Epidemiology) SAGE (Artificial Intelligence)AI agent with professional Socratic cognitive guidance. The control group (n=30) adopted general large language model (LLM)-based learning without systematic thinking intervention. Participants with clinically diagnosed severe mental disorders, cognitive dysfunction or inability to finish the complete research process were excluded. A baseline epidemiological knowledge pre-test confirmed no significant academic differences between the two groups via independent samples t-test, and all participants had no prior experience of AI-assisted medical learning.\n\nThe semi-structured interviews were conducted to collect students' authentic learning experiences, interactive perceptions and cognitive characteristics during the use of SAGE agent and general LLMs, providing qualitative evidence for the iterative optimization of AI teaching tools. All interviewees completed baseline assessments and preliminary AI learning trials, ensuring qualified professional foundation and genuine interactive experience. Conducted by trained researchers, the standardized interviews centered on three core themes: system usability and feedback clarity; AI-induced changes in information extraction, hypothesis formulation and causal inference; and common learning barriers including interactive obstacles, comprehension difficulties, cognitive overload and potential AI over-reliance. Transcribed interview data were analyzed through thematic analysis to summarize typical user experience patterns. Qualitative outcomes were triangulated with quantitative experimental results to revise the SAGE teaching protocol, optimize agent prompt chains and improve the interpretation of experimental findings.\n\nThe quasi-experiment consisted of three standardized stages. In the pre-test stage, all participants signed informed consent, completed a 25-item clinical epidemiology knowledge scale, an 11-item reasoning ability test and a demographic questionnaire to establish consistent baseline levels. In the intervention stage, the experimental group received standardized training in confounder identification and causal inference construction in strict accordance with the SAGE teaching protocol. The SAGE agent improved students' advanced epidemiological reasoning ability through continuous multi-round Socratic questioning and targeted cognitive guidance. The control group received equal-duration learning in the same experimental environment, only using conventional search engines and unguided LLMs for basic information retrieval without any cognitive and thinking intervention. All participants submitted screenshots to record their accurate AI tool usage duration after completing learning tasks.\n\nIn the post-test stage, all participants finished parallel-version epidemiological knowledge assessments and unified reasoning ability tests. Validated scales were adopted to evaluate students' cognitive load, system usability, learning satisfaction and academic self-confidence. Students' final scores of the Epidemiology course were collected as supplementary indicators of long-term learning effectiveness. Upon the completion of data collection, backend AI interaction logs were summarized and strictly screened. Invalid samples with insufficient interaction rounds or incomplete responses were excluded to ensure high data quality and reliable experimental conclusions.",[28,29],"an Intelligent Teaching Agent for the \"Epidemiology\" Course of the MBBS Program","Students' Critical Thinking, Practical Ability and Learning Outcomes",[31,32,33,34],"Artificial intelligence","Epidemiology","International medical curriculum","AI agent","RECRUITING","2026-08-03",{"date":38,"type":39},"2026-08-07","ACTUAL",{"date":41,"type":39},"2026-05-15",{"date":43,"type":22},"2027-01-31",{"name":45,"class":46},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100650225","phase-4-the-clinical-research-of-traditional-chinese-medicine-formula-100650225","NCT07746219","The Clinical Research of Traditional Chinese Medicine Formula","A Clinical Study on Bushen Huoxue Simiao Formula for Nourishing the Kidneys and Promoting Blood Circulation to Improve Postoperative Complications of Upper Urinary Tract Stones","Inclusion Criteria:\n\n1. Meet the Western medicine diagnostic criteria: Patients who need lithotripsy surgery and have a double J stent (4.7F, 28 cm) placed after surgery; plain film of kidney and upper bladder indicates normal position of ureteral stent and no need for stage II surgery.\n2. Meet the Traditional Chinese Medicine (TCM) diagnostic criteria.\n3. Aged between 18 and 80 years old (inclusive).\n4. Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with renal insufficiency stage 4 or 5, or acute renal failure.\n2. Secondary factors confirmed by examination, such as systemic lupus erythematosus or drug-induced kidney damage.\n3. Does not meet the diagnosis of upper urinary tract stones.\n4. Cases not within the scope of drug action.\n5. Long-term use of other relevant therapeutic drugs, or inability to stop medication immediately.\n6. Late-stage deformity, disability, or loss of labor ability.\n7. Complicated with severe primary diseases of heart, brain, liver, hematopoietic system, endocrine system, etc., or mental illness.\n8. Pregnant or lactating women.\n9. Patients in critical condition.\n10. Other conditions deemed unsuitable for enrollment by the researchers.","18 Years","80 Years",{"count":58,"type":22},80,[60],"PHASE4","This study examines the efficacy and safety of Bushen Huoxue Simiao formula for tonifying the kidneys and promoting blood circulation in treating postoperative complications of upper urinary tract stones, thereby providing evidence-based medical evidence and treatment strategies for clinical practice.",[63,64],"Urologic Injuries","Kidney Disease",[66,67,68],"Traditional Chinese Medicine","Renal Fibrosis","Renal Stone","NOT_YET_RECRUITING","2026-07-30",{"date":72,"type":39},"2026-08-04",{"date":74,"type":22},"2026-08-31",{"date":76,"type":22},"2028-08-31",{"name":45,"class":46},{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":16,"sex":17,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100649718","biomarkers-and-pharmacogenomics-for-precision-depression-therapy-100649718","NCT07738497","Biomarkers and Pharmacogenomics for Precision Depression Therapy","Study on Multidimensional Biomarkers of Depression and Individualized Therapy Based on Pharmacogenomic Technology","Inclusion Criteria:\n\n1. Clinical diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria\n2. Age between 18 and 60 years\n3. Baseline HAMD-17 total score ≥ 17\n4. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. History of other psychiatric disorders (e.g., bipolar disorder, schizophrenia)\n2. Presence of severe physical illnesses or major central nervous system diseases\n3. History of sedative-hypnotic, alcohol, or substance abuse\n4. Pregnancy, lactation, or planning to become pregnant during the study\n5. Significant abnormalities in ECG, complete blood count, or liver\u002Fkidney\u002Fthyroid function tests","14 Years","60 Years",{"count":88,"type":22},220,[25],"Background: The clinical management of major depressive disorder (MDD) is hampered by the lack of objective biomarkers and high inter-individual variability in drug response, with conventional antidepressants achieving only a 50% response rate.\n\nObjective and Design: This prospective, randomized, parallel-controlled trial aims to enroll 220 MDD patients, who will be allocated 1:1 to either a pharmacogenomics (PGx)-guided therapy group (treatment selection based on genetic testing) or a conventional treatment group (treatment as usual per guidelines), with a 12-week follow-up. Additionally, a matched healthy control cohort will be included for cross-sectional biomarker comparisons.\n\nIntervention and Outcomes: Patients in the PGx group undergo buccal swab testing for key genetic polymorphisms (e.g., CYP2D6, CYP2C19) to inform antidepressant type and dosage. The primary outcome is the 12-week response rate (≥50% reduction in HAMD-17 score from baseline). Secondary outcomes include remission rate, incidence of adverse drug reactions, and medication adjustment frequency.\n\nExploratory Aims: Multidimensional baseline data-including resting-state fMRI (VMHC), peripheral blood biomarkers (inflammatory cytokines, thyroid function, BDNF), urinary metabolites, and gut microbiome-will be integrated to construct a predictive model for treatment efficacy and to identify novel MDD biomarkers.\n\nScientific Significance: This study seeks to validate the clinical utility of PGx-guided prescribing and to advance the shift from symptom-based diagnosis towards a biological-characteristic-based precision medicine framework for depression.",[92],"Depression \u002F Major Depressive Disorder",[94,95,96,97,98,99],"Pharmacogenetics","Personalized Medicine","Biomarkers","Inflammation","Antidepressive Agents","Magnetic Resonance Imaging","2026-07-29",{"date":102,"type":39},"2026-07-31",{"date":104,"type":22},"2026-07-01",{"date":106,"type":22},"2029-01-19",{"name":45,"class":46},{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":115,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100649546","yiwu-cold-knife-technique-versus-electrocision-for-multiple-endometrial-polyps-100649546","NCT07737301","Yiwu Cold Knife Technique Versus Electrocision for Multiple Endometrial Polyps","Non-inferiority Comparison of Cold Knife Hysteroscopy (Yiwu Technique) Versus Electrocision for the Treatment of Multiple Endometrial Polyps: A Prospective Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\nAged 20 to 48 years. Regular menstrual cycles (22-35 days); no need for postoperative artificial cycle therapy. Patients requiring long-term medication such as those with PCOS are excluded.\n\nVoluntarily decline Mirena insertion, oral contraceptives or other progestogen therapy after surgery.\n\nDiagnosed with multiple endometrial polyps confirmed by at least one transvaginal ultrasound examination.\n\nScheduled to undergo hysteroscopic treatment. Generally good health status apart from endometrial polyps. Normal cervical screening results, or results requiring no therapeutic intervention after assessment.\n\nNo pregnancy plan within 1 year after hysteroscopic surgery. Able to provide written informed consent.\n\nExclusion Criteria:\n\nPostmenopausal women. Irregular menstrual cycles requiring postoperative hormonal intervention (e.g., polycystic ovary syndrome, PCOS).\n\nPregnant or breastfeeding women (interval between delivery, miscarriage or lactation and treatment initiation less than 3 months).\n\nHistory of endometrial ablation, pelvic radiation therapy, etc. Current use of tamoxifen or similar agents. Confirmed malignant genital tract tumor or breast cancer. Poor follow-up compliance and inability to complete 1-year follow-up. Other conditions deemed inappropriate for enrollment by investigators. Concurrent participation in another clinical drug trial. Inability to comply with the study protocol for any reason. Concurrent uterine malformation requiring synchronous surgery, moderate or severe intrauterine adhesions, embedded intrauterine device, submucous myoma greater than 1 cm, and other similar conditions.\n\nCombined severe internal diseases or surgical contraindications.","FEMALE","20 Years","48 Years",{"count":119,"type":22},850,[25],"\\# Clinical Trial Summary Template (Based on your endometrial polyp study)\n\nThe goal of this clinical trial is to learn if cold knife hysteroscopic polypectomy (Yiwu procedure) works to treat multiple endometrial polyps in women. It will also learn about the surgical safety of cold knife hysteroscopic polypectomy (Yiwu procedure). The main questions it aims to answer are:\n\nDoes cold knife hysteroscopic polypectomy (Yiwu procedure) achieve a 1-year postoperative recurrence rate that is non-inferior to electroresection hysteroscopic polypectomy? What intraoperative and postoperative adverse events and complications do participants experience after receiving either surgical treatment? Researchers will compare cold knife hysteroscopic polypectomy (Yiwu procedure) to standard electroresection hysteroscopic polypectomy to verify whether the cold knife technique can reduce endometrial polyp recurrence without increasing surgical risks.\n\nParticipants will:\n\nReceive either cold knife hysteroscopic polypectomy or conventional electroresection hysteroscopic polypectomy as standardized surgery Attend clinic follow-up visits at 3, 6 and 12 months after surgery for physical examinations and transvaginal ultrasound scans Complete clinical assessment records including menstrual status, abnormal uterine bleeding symptoms, pain conditions and patient satisfaction scores throughout the 1-year follow-up period",[123],"Yiwu Cold Knife Technique for Multiple Endometrial Polyps",[125,126,127,128,129,130,131,132,133,134],"Endometrial Polyps","Hysteroscopic polypectomy","Cold knife hysteroscopy","Electroresection hysteroscopy","Endometrial polyps recurrence","Abnormal uterine bleeding","Uterine benign lesions","Minimally invasive uterine surgery","Multi-center randomized controlled non-inferiority trial","1-year postoperative follow-up","2026-07-27",{"date":70,"type":39},{"date":138,"type":22},"2026-08-01",{"date":140,"type":22},"2029-06-01",{"name":45,"class":46},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":47},"100648467","the-preventive-and-therapeutic-effects-of-spirulina-preparations-on-ulcers-of-oral-mucosa-100648467","NCT07723612","The Preventive and Therapeutic Effects of Spirulina Preparations on Ulcers of Oral Mucosa","The Preventive and Therapeutic Effects of Spirulina Preparations on Recurrent Aphthous Ulcers of the Oral Mucosa","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Patients with radiation-induced oral mucositis (RIOM), recurrent aphthous stomatitis (RAS), or other clinically diagnosed oral ulcers, confirmed by clinical examination.\n* Presence of at least one clinically active oral ulcer at the time of enrollment.\n* Able to understand the study procedures and provide written informed consent.\n* Willing and able to comply with all study procedures, follow-up visits, and assessments.\n\nExclusion Criteria:\n\n* Previous radiotherapy to the head and neck region.\n\n  * Known allergy or hypersensitivity to spirulina or its components.\n  * Severe hepatic, renal, cardiovascular, or other uncontrolled systemic diseases.\n  * Pregnancy or breastfeeding.\n  * Participation in another interventional clinical trial during the study period.\n  * Any condition that, in the investigator's opinion, would interfere with study participation or outcome assessment.","100 Years",{"count":151,"type":22},40,[25],"This is a prospective, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of spirulina supplementation in patients with radiation-induced oral mucositis (RIOM) receiving radiotherapy for head and neck cancer. Participants will be randomly assigned to receive either spirulina tablets or placebo in addition to standard oral care during radiotherapy. The primary objective is to determine whether spirulina reduces the severity of oral mucositis. Secondary outcomes include the incidence and duration of severe oral mucositis, oral pain, nutritional status, quality of life, treatment interruption, and adverse events. The findings of this study may provide evidence for an effective and safe adjunctive intervention to improve the management of radiation-induced oral mucositis and enhance the quality of life of patients undergoing radiotherapy.",[155,156],"Recurrent Aphthous Stomatitis","Mouth Ulcer",[158],"Radiation-induced oral mucositis Recurrent aphthous stomatitis Oral ulcer Spirulina Oral microbiota Saliva biomarkers Supportive care","2026-07-21",{"date":161,"type":39},"2026-07-23",{"date":163,"type":39},"2026-06-01",{"date":165,"type":22},"2028-07-01",{"name":45,"class":46},{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100648026","dynamic-prediction-of-sleep-protection-demand-on-the-first-postoperative-night-and-its-influence-on-ward-process-after-thoracoscopic-lobectomy-or-segmentectomy-100648026","NCT07716085","Dynamic Prediction of Sleep Protection Demand on the First Postoperative Night and Its Influence on Ward Process After Thoracoscopic Lobectomy or Segmentectomy","Dynamic Prediction of First-Night Sleep Protection Needs After Thoracoscopic Lobectomy\u002FSegmentectomy and Analysis of the Impact of Ward Routines","Inclusion Criteria:\n\n\\- Aged 18 years or older; Scheduled for elective video-assisted thoracoscopic surgery (VATS) lobectomy or segmentectomy; Planned postoperative admission to a general thoracic surgery ward; American Society of Anesthesiologists (ASA) physical status classification I-III; Capable of understanding questionnaires and verbal communication; Prospective cohort participants who voluntarily enroll in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Emergency or trauma-related surgery; Planned direct postoperative admission to the intensive care unit (ICU); Severe cognitive impairment, delirium, or acute phase of psychiatric disorders; Severe hearing, speech or visual impairment precluding completion of assessments; Confirmed pregnancy or breastfeeding status; Chronic long-term use of sedative-hypnotics with unassessable baseline sleep status; Subjects deemed unlikely to complete key data collection or follow-up at the investigator's discretion.",{"count":175,"type":22},400,"OBSERVATIONAL","This study combines retrospective data analysis with a single-center prospective non-interventional cohort study to understand postoperative sleep disturbance on the first night after video-assisted thoracoscopic (VATS) lobectomy or segmentectomy. It mainly wants to answer the question: Can perioperative data collected along the clinical timeline dynamically predict which patients will experience clinically significant sleep disturbance on their first postoperative night? Participants undergoing elective VATS lung resection will have multidimensional data systematically collected from preoperative screening (including PSQI and GAD-7), intraoperative anesthetic parameters, PACU-to-ward handover, pre-bedtime symptom burden, and follow-up through 1 month. Three dynamic prediction models (M0 preoperative screening, M1 early postoperative update, and M2 pre-bedtime main model) will be developed using logistic regression with RCSQ-assessed sleep disturbance as the primary outcome, while an explanatory model will quantify the impact of nighttime disruptions such as intravenous infusions, vital sign monitoring, nursing entries, and awakenings.",[179],"Postoperative Sleep Disturbance",[181,182,183,184],"postoperative sleep disturbance","video-assisted thoracoscopic (VATS) lobectomy\u002Fsegmentectomy","dynamic prediction model","ward workflow burden","2026-07-16",{"date":159,"type":39},{"date":161,"type":22},{"date":189,"type":22},"2027-10-30",{"name":45,"class":46},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":207,"leadSponsor":209,"locationsCount":4},"100647690","a-prospective-trial-of-oral-lead-chelation-to-slow-renal-function-decline-in-lead-loaded-type-2-diabetic-nephropathy-patients-100647690","NCT07709871","A Prospective Trial Of Oral Lead Chelation To Slow Renal Function Decline In Lead-Loaded Type 2 Diabetic Nephropathy Patients","A Prospective Study On The Effect Of Oral Chelator Therapy On Delaying Renal Function Progression In Type 2 Diabetic Nephropathy Patients With Elevated Lead Burden","Inclusion Criteria:\n\n1. Diagnosed with type 2 diabetic nephropathy;\n2. Baseline blood lead level ≥ 5 μg\u002FdL;\n3. Chronic kidney disease stage ≤ 3;\n4. 24-hour urinary protein \\\u003C 8 g;\n5. Age ≥ 18 years;\n6. Able to voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Combined hypertension or hyperlipidemia;\n2. Confirmed history of autoimmune diseases;\n3. Personal history of malignant tumors;\n4. Reversible renal insufficiency (malignant hypertension, active urinary tract infection, recent use of nephrotoxic drugs);\n5. Previous occupational lead exposure history;\n6. Known drug allergy to dimercaptosuccinic acid;\n7. Unable to complete regular follow-up visits.",{"count":199,"type":22},42,[25],"This is a single-arm prospective clinical study conducted at The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Previous basic research has found that patients with type 2 diabetic nephropathy have higher blood lead levels than ordinary people, and lead accumulation may accelerate kidney function decline. A total of 42 eligible participants will be enrolled, who are diagnosed with type 2 diabetic nephropathy, have baseline blood lead ≥5 µg\u002Fdl, CKD stage ≤3 and 24-hour urinary protein \\\u003C8 g. All subjects will receive oral dimercaptosuccinic acid (DMSA) capsules for lead removal according to standardized treatment courses for up to 3 months. During treatment, blood lead, urine lead, renal function and other indicators will be tested monthly. After the 3-month intervention, all participants will be followed up for 12 months, with relevant laboratory examinations conducted every 3 months to observe changes in renal function. The main goal of this study is to evaluate whether oral lead chelation therapy can slow the progression of kidney damage in patients with high lead burden and type 2 diabetic nephropathy, and provide clinical evidence for the intervention of lead-induced kidney injury in diabetic populations. Patients with hypertension, hyperlipidemia, autoimmune diseases, malignant tumor history, previous occupational lead exposure or drug allergies will not be enrolled. No healthy volunteers will be recruited, and individual raw patient data will not be shared externally after the study.",[203],"Type 2 Diabetic Nephropathy With Elevated Blood Lead Burden",{"date":205,"type":39},"2026-07-17",{"date":138,"type":22},{"date":208,"type":22},"2029-01-01",{"name":45,"class":46},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":226,"locationsCount":4},"100647287","intravenous-chelators-in-lead-burdened-type-2-diabetic-nephropathy-100647287","NCT07706946","Intravenous Chelators in Lead-Burdened Type 2 Diabetic Nephropathy","A Prospective Study on Intravenous Chelator Therapy for Slowing Renal Function Progression in Patients With Type 2 Diabetic Nephropathy Combined With Lead Burden","Inclusion Criteria:\n\n* 1\\. Diagnosed with type 2 diabetic nephropathy; 2. Baseline blood lead level ≥5 µg\u002Fdl; 3. Chronic kidney disease stage ≤3; 4. 24-hour urinary protein \\\u003C 8 g; 5. Age ≥18 years old; 6. Able to provide written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Combined hypertension; 2. Combined hyperlipidemia; 3. History of autoimmune diseases; 4. Personal history of malignant tumors; 5. Reversible renal insufficiency (malignant hypertension, urinary tract infection, recent use of nephrotoxic drugs); 6. Past occupational lead exposure history; 7. Drug allergy to calcium disodium edetate; 8. Unable to complete follow-up or provide informed consent.",{"count":199,"type":22},[25],"Based on previous basic experiments revealing that patients with type 2 diabetic nephropathy exhibit higher blood lead levels than the general population, this study aims to systematically evaluate the impacts of short-term and long-term blood lead exposure on renal function progression in such patients, so as to provide novel epidemiological evidence for clinical intervention.",[221],"Lead-Burdened Type 2 Diabetic Nephropathy","2026-07-12",{"date":185,"type":39},{"date":138,"type":22},{"date":208,"type":22},{"name":45,"class":46},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":242,"leadSponsor":244,"locationsCount":4},"100646587","development-and-application-of-an-oral-care-protocol-for-stroke-patients-with-orotracheal-intubation-100646587","NCT07690475","Development and Application of an Oral Care Protocol for Stroke Patients With Orotracheal Intubation","Inclusion Criteria:\n\n* Diagnosed as a patient with stroke;Maintaining an oral tracheal tube insertion;The indwelling time of the oral tracheal tube should be at least 7 consecutive days;No oral diseases before intubation;Tooth count ≥ 10\n\nExclusion Criteria:The patient had been intubated for more than 48 hours before admission;Patients who have had their endotracheal tubes replaced during the procedure;Patients who were discharged halfway through their treatment\n\n\\-",{"count":21,"type":22},[25],"Develop a standardized oral care protocol for stroke patients undergoing orotracheal intubation based on evidence-based practice, and validate its effectiveness through clinical trials.",[237],"Develop an Oral Care Plan and Verify it","2026-07-02",{"date":240,"type":39},"2026-07-08",{"date":138,"type":22},{"date":243,"type":22},"2027-05-01",{"name":45,"class":46},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":16,"sex":17,"minAge":116,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":261,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":266,"leadSponsor":268,"locationsCount":4},"100646797","a-practical-exploration-of-developing-a-full-english-orthopedic-nursing-curriculum-based-on-deepseek-intelligence-100646797","NCT07688499","A Practical Exploration of Developing a Full-English Orthopedic Nursing Curriculum Based on DeepSeek Intelligence","Inclusion Criteria:\n\n* ① On-duty nurses in the orthopedics department ② Obtained the nurse professional qualification certificate ③ Obtained the patient's informed consent and signed the informed consent form ④ The research was approved by the ethics committee of this hospital.\n\nExclusion Criteria:\n\n* Nurses who have not completed 1\u002F2 of the course content","40 Years",{"count":253,"type":22},20,[25],"This educational reform study aims to explore whether a full English course built on the DeepSeek artificial intelligence platform can improve orthopedic nurses' professional English competence. It will also examine nurses' satisfaction with AI-assisted teaching. The main questions it seeks to answer include:\n\nWill the DeepSeek-based full English course improve orthopedic nurses' professional English test scores?\n\nWill nurses' transcultural nursing self-efficacy and nurse-patient therapeutic interaction ability improve after the course training?\n\nWhat are nurses' experiences when using the DeepSeek AI platform for learning?\n\nResearchers will compare the English proficiency changes of the same group of orthopedic nurses before and after the training to observe the course effects.\n\nParticipants will:\n\nAttend an 11-week full English course based on the DeepSeek platform, approximately 1-2 hours per week\n\nComplete a professional English written test and an oral proficiency assessment before and after the training\n\nComplete the Transcultural Self-Efficacy Tool (TSET-CV) and the Nurse-Patient Therapeutic Interaction Scale (NuPTIS) before and after the training\n\nComplete a teaching satisfaction and AI learning experience questionnaire after the course",[257,258,259,260],"Orthopedic Nursing","Education, Nursing","Artificial Intelligence","Language",[262],"DeepSeek; artificial intelligence; orthopedic nursing; full English course; nursing English teaching; transcultural nursing; nursing education",{"date":264,"type":39},"2026-07-07",{"date":104,"type":22},{"date":267,"type":22},"2027-07-01",{"name":45,"class":46},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":17,"minAge":277,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":47},"100646788","phase-4-evaluation-system-for-lecanemab-efficacy-using-gold-electrode-ecl-to-monitor-alzheimers-biomarkers-100646788","NCT07688460","Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers","Construction of a Lecanemab Therapeutic Efficacy Evaluation System Based on Mesoporous Gold Electrode Surface-enhanced Electrochemiluminescence for Monitoring Dynamic Changes of Alzheimer's Disease Plasma Biomarkers","ECL-Lecanemab","Inclusion Criteria:\n\n1. Diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's dementia.\n2. Age between 50 and 90 years (inclusive).\n3. Confirmed presence of amyloid pathology (positive amyloid PET scan or CSF biomarkers).\n4. Mini-Mental State Examination (MMSE) score between 22 and 30.\n5. Clinical Dementia Rating (CDR) global score of 0.5 or 1.\n6. Stable dose of allowed concomitant medications for at least 4 weeks prior to screening.\n7. Willing and able to comply with the study procedures, including blood draws for ECL monitoring.\n8. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Significant neurological disorders other than Alzheimer's disease (e.g., stroke, Parkinson's disease).\n2. History of brain hemorrhage, microbleeds, or superficial siderosis on MRI.\n3. Use of anticoagulants that cannot be safely interrupted.\n4. Severe systemic diseases (e.g., severe heart failure, uncontrolled diabetes) that may interfere with the study.\n5. Known hypersensitivity to Lecanemab or any excipients.\n6. Pregnant or breastfeeding women.\n7. Participation in another interventional clinical trial within the last 30 days.","50 Years","90 Years",{"count":280,"type":22},100,[60],"This study aims to evaluate the therapeutic efficacy of Lecanemab in patients with Alzheimer's disease. The researchers will use a novel detection method based on mesoporous gold electrode surface-enhanced electrochemiluminescence (ECL) to monitor specific biomarkers in the patients' plasma. By tracking changes in these biomarkers, the study seeks to determine how effectively Lecanemab treats the disease and to validate this new ECL-based monitoring system as a useful tool for clinical assessment.",[284],"Alzheimer Disease",{"date":264,"type":39},{"date":287,"type":22},"2026-07-10",{"date":289,"type":22},"2029-03-30",{"name":45,"class":46},{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":307,"leadSponsor":309,"locationsCount":4},"100646702","clinical-pharmacist-led-perioperative-pain-management-in-orthopedic-surgery-an-effectiveness-evaluation-100646702","NCT07688486","Clinical Pharmacist-Led Perioperative Pain Management in Orthopedic Surgery: An Effectiveness Evaluation","Clinical Pharmacist-Involved Perioperative Pain Management Model Construction and Effectiveness Evaluation in Orthopedic Surgery","nclusion Criteria ： Patients scheduled for elective orthopedic surgery (e.g., total hip\u002Fknee arthroplasty, fracture fixation).\n\nAge ≥ 18 years. American Society of Anesthesiologists (ASA) physical status I-III. Able to understand and communicate pain intensity (e.g., use VAS score). Willing to provide informed consent.\n\nExclusion Criteria Emergency surgery or trauma patients unable to communicate. History of chronic opioid use or substance abuse. Severe cognitive impairment or psychiatric disorders preventing cooperation. Known allergy or contraindication to study medications (analgesics). Pregnant or breastfeeding women. Participation in other clinical trials that may interfere with this study.","99 Years",{"count":300,"type":22},600,[25],"This study aims to evaluate the effectiveness of a clinical pharmacist-led perioperative pain management model in orthopedic surgery. It is a randomized controlled trial involving patients undergoing major orthopedic procedures. Participants will be assigned to either a standard care group or an intervention group receiving comprehensive pharmaceutical care, including preoperative medication reconciliation, intraoperative monitoring, and postoperative analgesic optimization. The primary outcome is the incidence of moderate-to-severe postoperative pain. Secondary outcomes include opioid consumption, adverse drug reactions, and patient satisfaction. This study seeks to establish an evidence-based protocol for optimizing pain management in orthopedic settings.",[304],"Postoperative Pain",{"date":264,"type":39},{"date":70,"type":22},{"date":308,"type":22},"2027-11-30",{"name":45,"class":46},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":17,"minAge":318,"maxAge":19,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":322,"conditions":323,"keywords":325,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":4},"100647065","non-suicidal-self-injury-digital-psychotherapy-trial-100647065","NCT07683234","Non-Suicidal Self-Injury Digital Psychotherapy Trial","A Novel Digital Psychotherapy Intervention for Non-Suicidal Self-Injury in Adolescents: A Randomized Controlled Trial","NSSI-DPT","Inclusion Criteria:\n\n* Diagnosis of Non-Suicidal Self-Injury (NSSI) according to DSM-5, confirmed by two psychiatrists with senior professional titles.\n* Adolescents aged 12-25 years, any gender.\n* Willing to participate voluntarily and with good insight.\n\nExclusion Criteria:\n\n* Presence of severe mental disorders (e.g., schizophrenia, schizoaffective disorder, substance use disorder, intellectual disability).\n* Major central nervous system diseases (e.g., history of head trauma or infection, intracranial tumor, cerebrovascular disease, epilepsy).\n* History of major physical diseases (e.g., malignancy, myocardial infarction, liver or kidney dysfunction).\n* History of abuse of sedative-hypnotics, alcohol, or other psychoactive substances.\n* History of suicide attempt, current high suicide risk, or current suicidal behavior\u002Fideation.\n* Pregnancy or breastfeeding.","12 Years",{"count":320,"type":22},110,[25],"The goal of this randomized, parallel-controlled clinical trial is to investigate multi-dimensional biomarkers (blood, brain imaging, clinical information, and symptom assessment) in adolescents with Non-Suicidal Self-Injury (NSSI) and to evaluate the therapeutic and prognostic effects of a novel digital psychological intervention plus treatment as usual (TAU) compared to TAU alone in this population.\n\nThe main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\nWhat are the distinct biomarker profiles (e.g., inflammatory, endocrine, neuroimaging) associated with adolescent NSSI? Does the novel digital psychological intervention (based on CBT and DBT) combined with TAU lead to a higher clinical response rate (≥25% reduction in NSSI scale score from baseline) at 8 and 16 weeks compared to TAU alone?\n\nIf there is a comparison group: Researchers will compare the digital intervention plus TAU group to the TAU-only group to see if adding the digital intervention significantly improves NSSI symptom reduction, depressive symptoms (HAMD-24 response rate), and long-term outcomes.\n\nParticipants will:\n\nUndergo baseline assessments including blood sampling (inflammatory and endocrine markers, routine biochemistry), structural and resting-state functional MRI, and clinical scales (e.g., HAMD, HAMA).\n\nUse a smartphone app for 8 weeks, completing 16 self-guided digital modules (2 per week, 15-25 minutes each) based on CBT and DBT, covering topics such as NSSI psychoeducation, safety planning, emotion regulation, distress tolerance, mindfulness, and relapse prevention.\n\nComplete daily Ecological Momentary Assessment (EMA) questionnaires (1-2 minutes) on self-harm urge intensity, mood, and coping skills used; receive Ecological Momentary Intervention (EMI) when high urge is detected.\n\nReceive low-intensity remote coaching (one 20-30 min onboarding call, then two brief contacts per week via text\u002Fcall\u002Femail) to support app adherence.\n\nAttend follow-up assessments at week 4, week 8 (intervention endpoint), and week 16 (study endpoint) for repeated clinical and outcome measures.",[324],"Non-suicidal Self-injury (NSSI)",[326,327,328,329,330],"Non-Suicidal Self-Injury (NSSI)","adolescents","digital psychological intervention","randomized controlled trial (RCT)","dialectical behavior therapy (DBT)","2026-06-28",{"date":333,"type":39},"2026-07-06",{"date":335,"type":22},"2026-06-15",{"date":337,"type":22},"2028-12-31",{"name":45,"class":46},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":47},"100646955","keloid-pathogenesis-and-fibroblast-activation-study-100646955","NCT07682636","Keloid Pathogenesis And Fibroblast Activation Study","Mechanisms Of Keloid Fibroblast Activation And Potential Therapeutic Targets: A Tissue-Based Translational Study","KPS","Inclusion Criteria:\n\n* Clinically diagnosed with keloid.\n* Age 18 years or older.\n* Scheduled to undergo surgical treatment at the study hospital.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Severe systemic disease.\n* History of neurologic disease, alcoholism, postherpetic neuralgia, HIV infection, hypothyroidism, diabetes mellitus, or prior cancer chemotherapy.\n* Other skin diseases within 5 cm of the keloid lesion, such as eczema.\n* Systemic treatment within 7 days before enrollment or keloid-specific treatment within 6 weeks before enrollment, including intralesional corticosteroid injection, cryotherapy, topical medication, or silicone gel sheeting.\n* Hormone or immunosuppressive therapy within 3 months before enrollment.\n* Pregnancy or breastfeeding.\n* Considered unsuitable for participation by the investigator.\n* Refusal to participate in the study.",{"count":253,"type":22},"Keloids are benign fibroproliferative skin disorders characterized by excessive fibroblast activation and extracellular matrix deposition. The molecular mechanisms underlying keloid formation remain incompletely understood. This prospective observational study aims to investigate the biological characteristics of keloid tissue by comparing surgically resected keloid specimens with adjacent normal skin obtained from the same patients. Histological and molecular analyses, including histopathology, polymerase chain reaction (PCR), Western blotting, and related laboratory assays, will be performed to identify signaling pathways and key regulatory factors associated with fibroblast activation. The findings may improve the understanding of keloid pathogenesis and identify potential therapeutic targets for future treatment.",[350,351],"Keloids","Fibroblast",{"date":333,"type":39},{"date":354,"type":39},"2025-05-10",{"date":356,"type":22},"2028-05-30",{"name":45,"class":46},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":16,"sex":115,"minAge":55,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":367,"conditions":368,"keywords":372,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":47},"100642298","bone-management-in-pregnancy-outcomes-in-epilepsy-100642298","NCT07651709","Bone Management in Pregnancy Outcomes in Epilepsy","Bone Health Management on Pregnancy Outcomes in Women With Epilepsy: Randomized Study","Inclusion Criteria:\n\n* Diagnosis of focal or generalized epilepsy as defined by the International League Against Epilepsy.\n* Women of childbearing age, aged ≥18 years, planning pregnancy or in early pregnancy (≤16 weeks gestation, confirmed by last menstrual period or ultrasound) - single pregnancy.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Pre-existing conditions affecting bone metabolism: primary hyperparathyroidism, Paget's disease, multiple myeloma, chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin), cirrhosis (Child-Pugh B\u002FC), or untreated hyper\u002Fhypothyroidism.\n* History of metabolic complications: hypercalcemia (serum Ca²⁺ \\>10.5 mg\u002FdL), nephrolithiasis, or granulomatous diseases.\n* Recent\u002Fcurrent use of bone-modifying drugs: bisphosphonates, glucocorticoids (≥5 mg\u002Fday prednisone equivalent for \\>1 month), or loop diuretics within the past year.\n* Ultrasound shows fetal malformation.\n* Presence of other severe systemic diseases deemed unsuitable for study participation by the investigator.",{"count":58,"type":22},[25],"This study is aimed to evaluate the efficacy of bone health management in improving pregnancy outcomes among WWE, and establish evidence-based vitamin D supplementation strategies for childbearing-age WWE.",[369,370,371],"Epilepsy","Pregnant Woman","Bone Health",[373,374],"epilepsy","pregnancy","2026-06-11",{"date":377,"type":39},"2026-06-16",{"date":379,"type":22},"2026-06",{"date":381,"type":22},"2035-01",{"name":45,"class":46},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":47},"100635838","a-prospective-single-centre-observational-cohort-study-on-the-efficacy-and-safety-of-bacterial-lysate-om-85-in-combination-with-antihistamines-for-the-treatment-of-chronic-spontaneous-urticaria-csu-100635838","NCT07557888","A Prospective, Single-centre, Observational Cohort Study on the Efficacy and Safety of Bacterial Lysate (OM-85) in Combination With Antihistamines for the Treatment of Chronic Spontaneous Urticaria (CSU)","A Prospective Clinical Study on the Efficacy and Safety of Bacterial Lysate (OM-85) Combined With Antihistamines in the Treatment of Chronic Spontaneous Urticaria (CSU): A Single-Centre, Observational, Cohort Study","Inclusion Criteria:\n\n1. The participants were fully informed of the purpose, procedure and risks of the study and voluntarily signed the informed consent form.\n2. Aged 18 to 65 (inclusive), no gender restrictions.\n3. Meets the CSU diagnostic criteria, with a disease duration of ≥6 weeks.\n4. Antihistamine resistance: Regular use of a standard dose (as recommended in the package leaflet) of a second-generation H1 antihistamine (e.g. desloratadine 5 mg, levocetirizine 5 mg, etc.) for at least 2 weeks prior to screening, but with symptoms still not effectively controlled. Defined as: a UAS7 score of ≥7 within 7 days prior to the screening visit (V1) and baseline visit (V2).\n5. Agree to maintain the type and dose of the baseline antihistamine throughout the trial.\n6. Agree not to consume any products that may significantly affect the gut microbiota during the trial (such as yoghurt containing probiotics, or probiotic\u002Fprebiotic supplements).\n7. At the baseline visit, the treatment regimen was clearly defined, and exposure status (OM-85 exposure group or non-exposure group) could be determined based on actual prescriptions and medication records.\n\nExclusion Criteria:\n\n1. Special types of urticaria: These primarily include physical urticaria (such as artificial urticaria, cold contact urticaria and cholinergic urticaria), urticarial vasculitis, and angioedema caused by hereditary or acquired C1 esterase inhibitor deficiency;\n2. Systemic use of glucocorticoids (oral or injectable) within the four weeks prior to screening;\n3. Exclude patients who have used immunosuppressants (such as cyclosporine, methotrexate, or Tripterygium wilfordii) within the previous four weeks;\n4. Exclude patients who have used biologics (such as omazulimab, dupilumab, etc.) within the previous three months;\n5. Exclude those who have used bacterial lysates (such as Panfuxu or Pidomod) or received vaccinations within the past three months;\n6. Key exclusion criteria for the microbiome study: use of oral or intravenous antibiotics within the four weeks prior to screening, or continuous use of probiotic supplements for more than one week.\n7. Patients with severe systemic autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.) may interfere with the assessment of immune mechanisms;\n8. A history of serious liver, kidney, heart, lung or blood disorders, or malignant tumours;\n9. Individuals known to be allergic to bacterial lysates and their excipients.\n10. Special populations: pregnant or breastfeeding women, or participants of childbearing age who do not intend to use contraception during the trial.\n11. Other: Participants who have taken part in other clinical trials involving medicinal products within the past 30 days; or where the investigator considers that there is poor compliance, a mental health condition, or any other circumstance rendering the participant unsuitable for the trial.","65 Years",{"count":392,"type":22},132,"A Prospective Clinical Study on the Efficacy and Safety of Bacterial Lysate (OM-85) Combined with Antihistamines in the Treatment of Chronic Spontaneous Urticaria (CSU): A Single-Centre, Observational, Cohort Study",[395],"Chronic Spontaneous Urticaria (CSU)","2026-05-04",{"date":398,"type":39},"2026-05-07",{"date":400,"type":22},"2026-05-01",{"date":402,"type":22},"2027-06-01",{"name":45,"class":46},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":412,"briefSummary":414,"conditions":415,"keywords":418,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":47},"100634863","phase-2-efficacy-and-safety-of-skb264-plus-anlotinib-in-egfr-tki-resistant-advanced-nsclc-with-liver-metastasis-100634863","NCT07545213","Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis","Inclusion Criteria:\n\nTo be eligible for this study, participants must meet all of the following criteria:\n\n1. Aged ≥ 18 years, both male and female;\n2. ECOG performance status score of 0-1;\n3. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) that is locally advanced (stage IIIB\u002FIIIC) or metastatic (stage IV) and not amenable to curative surgery and\u002For curative radiotherapy (with or without concurrent chemotherapy), according to the IASLC 9th edition lung cancer TNM staging system.\n4. At least one measurable target lesion in the liver (according to RECIST version 1.1);\n5. Has previously received EGFR-TKI therapy for locally advanced or metastatic NSCLC with treatment failure (radiographic disease progression)；\n6. Life expectancy ≥12 weeks.\n7. Adequate organ and bone marrow function (without receiving blood transfusion, recombinant human thrombopoietin, or colony-stimulating factor therapy within 2 weeks prior to the first dose), defined as follows:\n\n   1. Complete blood count: absolute neutrophil count (NEUT#) ≥ 1.5 × 10⁹\u002FL; platelet count (PLT) ≥ 100 × 10⁹\u002FL; hemoglobin ≥ 9 g\u002FdL;\n   2. Liver function: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) ≤ 2.5 × upper limit of normal (ULN); total bilirubin (TBIL) ≤ 1.5 × ULN;\n   3. Renal function: creatinine clearance (Ccr) ≥ 60 mL\u002Fmin (Cockcroft-Gault formula see appendix);\n   4. Cardiac function: left ventricular ejection fraction (LVEF) ≥ 50% as assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan;\n8. Female participants of childbearing potential and male participants with partners of childbearing potential must use a medically approved contraceptive method (e.g., intrauterine device, contraceptive pills, or condoms) during the study treatment period and for 6 months after the last dose;\n9. Participants voluntarily enroll in this study, sign the informed consent form, have good compliance, and cooperate with follow-up visits.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will not be enrolled in this study:\n\n1. Histologically or cytologically confirmed presence of small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma components;\n2. Previous treatment with TROP2-targeted therapy and\u002For topoisomerase I inhibitors;\n3. Has had other malignant tumors within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin;\n4. Known or screening-detected symptomatic active central nervous system (CNS) metastases or carcinomatous meningitis (Note: ① Patients who have been treated and have stable disease for ≥4 weeks and have discontinued systemic corticosteroids (at any dose) for \\>3 days may be enrolled. ② Patients with asymptomatic brain metastases (i.e., no neurological symptoms, no requirement for corticosteroids, and no lesion \\>1.5 cm) are eligible but require regular brain imaging as part of disease site evaluation)；\n5. Known history of allergy to the study drugs or their components, history of immunodeficiency, or history of organ transplantation;\n6. History of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment; current ILD or non-infectious pneumonitis; or suspected ILD or non-infectious pneumonitis that cannot be ruled out by imaging at screening; clinically severe pulmonary impairment due to concurrent pulmonary diseases, including but not limited to any underlying pulmonary disease (e.g., pulmonary embolism within 3 months prior to dosing, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.) or any autoimmune, connective tissue, or inflammatory disease that may affect the lungs (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.), or prior pneumonectomy;\n7. Active infection requiring systemic therapy within 2 weeks prior to the first dose;\n8. According to the investigator's judgment, presence of concomitant diseases that seriously jeopardize patient safety or affect the patient's ability to complete the study, including but not limited to hypertension uncontrolled by medication, severe diabetes, active infection, etc;\n9. Occurrence of arterial\u002Fvenous thrombotic events, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism, within 12 weeks prior to signing the informed consent form;\n10. Current active bleeding, or central lung cancer with potential for massive hemorrhage; or history of bleeding disorders (e.g., von Willebrand disease or hemophilia); clinically significant bleeding within 6 months prior to enrollment (e.g., gross hematuria, gastrointestinal bleeding, and hemoptysis); or receipt of therapeutic anticoagulants or aspirin within 14 days prior to enrollment;\n11. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or minor surgical procedure within 7 days prior to enrollment;\n12. Documented severe dry eye syndrome, severe meibomian gland disease and\u002For blepharitis, or a history of corneal disease that prevents or delays corneal healing;\n13. Any other conditions that, in the investigator's opinion, make the patient unsuitable for participation in this study.",{"count":411,"type":22},27,[413],"PHASE2","The goal of this clinical trial is to learn if the combination therapy with SKB264 and anlotinib works to treat EGFR-TKI-resistant, liver-metastatic non-squamous non-small cell lung cancer (NSCLC). It will also learn about the safety of the combination therapy with SKB264 and anlotinib. The main questions it aims to answer are:\n\nDoes combination therapy with SKB264 and anlotinib increase response rate and disease control rate, prolong duation of response and progressioin-free survival.\n\nWhat medical problems do participants have when taking combination therapy with SKB264 and anlotinib? Researchers will compare combination therapy with SKB264 and anlotinib to a historical data (the response rate of other drugs reported in literature) to see if combination therapy with SKB264 and anlotinib works better to treat EGFR-TKI-resistant, liver-metastatic non-squamous non-small cell lung cancer (NSCLC).\n\nParticipants will:\n\n1. receive SKB264 4 mg\u002Fkg intravenously on a 14-day cycle, and take anti-H1\u002FH2 antihistamines, acetaminophen, and dexamethasone is recommended before infusion for the first 4 infusions to prevent side effects; the regimen may be simplified starting from the 5th infusion.\n2. take anlotinib 10 mg orally once daily for 14 consecutive days, followed by a 7-day rest period.\n3. Visit the clinic once every week for checkups and tests",[416,417],"Non-small Cell Lung Cancer","EGFR Mutant Advanced Non-small Cell Lung Cancer",[419,420,421,422,423],"non-small cell lung cancer","NSCLC","EGFR-TKI resistance","SKB264","anlotinib","2026-04-16",{"date":426,"type":39},"2026-04-22",{"date":428,"type":22},"2026-04-20",{"date":430,"type":22},"2028-08-15",{"name":45,"class":46},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":47},"100619362","the-efficacy-and-safety-of-anti-inflammation-treatment-hirudoid-introduction-followed-by-yellow-light-therapy-combined-with-tofacitinib-and-doxycycline-in-chinese-adult-patients-with-mild-to-moderate-erythematous-telangiectatic-rosacea-100619362","NCT07343635","The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea","The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea: A Prospective Parallel Controlled Single-blind Cohort Study","Inclusion Criteria:\n\n* The subjects are male or female, aged 18 to 70 years (inclusive); they voluntarily participate in this study and sign the informed consent form.\n* They are diagnosed with erythematous telangiectatic rosacea, meeting the diagnostic criteria in the \"Chinese Guidelines for the Diagnosis and Treatment of Rosacea (2021)\".\n* At screening and baseline, the IGA score is 2 (mild) or 3 (moderate).\n* The subjects agree not to use any other rosacea treatment drugs (prescription or over-the-counter) during the study period.\n* The subjects are willing to minimize external factors that may trigger rosacea (such as spicy food, alcoholic beverages, prolonged sun exposure, etc.).\n* The subjects (including their partners) agree that they have no plans to conceive within 3 months after signing the informed consent form until the end of the last treatment and are willing to take effective contraceptive measures voluntarily.\n\nExclusion Criteria:\n\n* Diagnosed as papulopustular, hypertrophic, ocular rosacea or other special types of rosacea\n* Other facial skin diseases that were active during the screening period or baseline may interfere with the efficacy\u002Fsafety assessment of erythematous vasodilating rosacea, including but not limited to perioral dermatitis, facial keratosis, seborrheic dermatitis, and acne vulgaris. If the above-mentioned skin diseases were in clinical remission both during the screening period and at baseline, and the investigators determined that they would not affect the assessment of this study, they could be included.\n* Subjects who have underlying known diseases or medical conditions, or who have undergone major surgeries within the six months prior to screening, where, based on the researcher's judgment, the subjects are at risk (such as cancer, leukemia or cachexia in the blood system);\n* During the screening period or at baseline, researchers evaluate abnormal laboratory test results with significant clinical significance;\n* Those who have received LED light therapy for their faces in the past two weeks;\n* Those who have received laser, intense pulsed light (IPL), fractional microneedle radiofrequency treatment, CO2 exfoliating fractional laser treatment, electrocoagulation, dermabrasion, chemical peels, or any facial procedures (such as Thermage, etc.) for facial treatment in the past 6 weeks;\n* Facial active infections who are currently receiving or require systemic treatment (systemic antibiotics, antifungal, antiviral drugs) - including bacterial pustules, fungal folliculitis, herpeder-like skin lesions and massive proliferation of Demodex mites;\n* Local\u002Fsystemic treatment that did not complete an adequate elution period before baseline, including: Glucocorticoids (corticosteroids), calcineurin inhibitors (such as tacrolimus, pimecrolimus), Janus kinase inhibitors, epidermal growth factors (such as commercially available repair dressings containing recombinant human EGF), acne treatment drugs (such as azelaic acid, retinoids, benzoyl peroxide, traditional Chinese medicine\u002FChinese patent medicine treatment), Such as tanshinone, metronidazole tablets, etc.), immunomodulators, topical astringents\u002Fexfoliating products, antibiotics (such as macrolides, metronidazole), high-concentration vitamin A (10,000 units per day), anti-pruritus drugs (such as antihistamines), etc.\n* Use drugs that cause acne-like rashes simultaneously (such as azathioprine, haloperidol, halogens, lithium, systemic corticosteroids, phenytoin sodium, phenobarbital, testosterone, anabolic steroids, isoniazid);\n* Those who have used astringents\u002Fexfoliating products (cleansing or exfoliating products containing salicylic acid or alcohol) within the past 2 days or are planned to use them during the study period;\n* The subject has a history of alcohol abuse (drinking more than 14 units) within the past 2 years or a history of drug abuse within the past 5 years;\n* Individuals infected with human immunodeficiency virus (HIV), those in the active stage of hepatitis C virus (HCV) infection (positive for anti-HCV), or those in the active stage of hepatitis B virus (HBV) infection (HBV-DNA \\> 2000IU\u002FmL or 104 copies \u002Fml), or those with positive Treponema pallidum antibodies showing an active stage of infection;\n* Female subjects who plan to become pregnant or breastfeed during the study period;\n* Those who are sensitive to light or use photosensitive drugs;\n* People who are allergic to Hirudoid, tofacitinib, doxycycline, hydroxychloroquine or their ingredients.","70 Years",{"count":441,"type":22},186,[25],"The efficacy and safety of anti-inflammation treatment (Hirudoid introduction followed by yellow light therapy) combined with tofacitinib and doxycycline in Chinese adult patients with mild to moderate erythematous telangiectatic rosacea: A prospective parallel controlled single-blind cohort study",[445],"Erythematotelangiectatic Rosacea","2026-03-20",{"date":448,"type":39},"2026-03-24",{"date":450,"type":39},"2026-02-01",{"date":267,"type":22},{"name":45,"class":46},{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":390,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100616117","phase-4-rws-of-of-liraglutide-alone-and-in-combination-with-orlistat-for-weight-loss-in-overweightobese-patients-100616117","NCT07301437","RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight\u002FObese Patients.","A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight\u002FObese Patients.","Inclusion Criteria:\n\n* BMI: ≤ 35 kg\u002Fm² and ≥ 30 kg\u002Fm², or ≥ 27 kg\u002Fm² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)\n* Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.\n* No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.\n\nExclusion Criteria:\n\n* Allergy to liraglutide, orlistat or excipients\n* Severe liver and kidney dysfunction: ALT or AST\\> three times the upper limit of normal, or eGFR \\\u003C30 mL\u002Fmin\n* Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism\u002Fhypothyroidism\n* Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers\n* Pregnant or lactating women\n* Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).",{"count":461,"type":22},120,[60],"To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight\u002Fobese patients.",[465],"Overweight and Obese Adults",{"date":467,"type":39},"2026-03-23",{"date":400,"type":22},{"date":470,"type":22},"2027-08-31",{"name":45,"class":46},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":23,"phases":481,"briefSummary":482,"conditions":483,"keywords":486,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":489,"leadSponsor":490,"locationsCount":4},"100615218","phase-4-the-effect-of-alogliptin-combined-with-actoplus-met-on-glucose-and-lipid-metabolism-and-pancreatic-function-in-patients-with-t2dm-complicated-with-mafld-100615218","NCT07289750","The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD","The Effect of Alogliptin Combined With Pioglitazone and Metformin Hydrochloride Tablets on Glucose and Lipid Metabolism and Islet Function in Patients With Type 2 Diabetes Mellitus Complicated With Metabolic Dysfunction-associated Fatty Liver Disease","Inclusion Criteria:\n\n* Clinical diagnosis of T2DM\n* Clinical diagnosis of MAFLD\n* HbA1c: 6.5-9.5%\n* BMI: 19-35 kg\u002Fm2\n* No hypoglycemic drugs or insulin have been used within half a year\n\nExclusion Criteria:\n\n* Severe infections, surgeries and other emergency\n* Other types of diabetes\n* Severe cardiovascular, brain, liver and kidney disorders\n* Malignant tumor","75 Years",{"count":58,"type":22},[60],"To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.",[484,485],"T2DM","MAFLD",[484,485],{"date":448,"type":39},{"date":400,"type":22},{"date":470,"type":22},{"name":45,"class":46},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":479,"enrollmentInfo":498,"targetDuration":4,"studyType":23,"phases":500,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":511,"leadSponsor":513,"locationsCount":4},"100623317","phase-2-a-clinical-study-on-the-treatment-of-metastatic-colorectal-cancer-at-the-second-line-or-beyond-100623317","NCT07395063","A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.","A Single-arm, Open-label Clinical Study of Irinotecan Liposome Combined With Capecitabine, Bevacizumab and Camrelizumab as Second-line or Higher Treatment for Patients With Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* Patients pathologically diagnosed with colorectal cancer;\n* Received systemic treatment on the first line;\n* Age: 18 to 75 years old, gender not limited.\n* There must be at least one measurable lesion as the target lesion (in accordance with the RECIST v1.1 standard);\n* ECOG: 0-1;\n* Expected survival period ≥3 months;\n* Women of childbearing age must undergo a blood pregnancy test within 3 days before randomization, and the result must be negative. They must also be willing to take appropriate contraceptive measures during the trial and for 6 months after the end of treatment. For men, it should be agreed to use appropriate methods of contraception during the study period and within 3 months after the end of treatment;\n* The subjects voluntarily joined this study and signed the informed consent form.\n\nExclusion Criteria:\n\n* Patients with wild-type RAS and BRAF, whose primary lesion is located in the left colorectal tract, but who have not received cetuximab as the first-line treatment\n* Patients with advanced colorectal cancer who have MSI-H or dMMR\n* Those with a history of other malignant diseases in the last five years, except for cured skin cancer and cervical carcinoma in situ\n* For patients with a history of uncontrolled epilepsy, central nervous system diseases or mental disorders, the researcher will determine that the clinical severity may prevent them from signing the informed consent form or affect their compliance with oral medication\n* Clinically severe (i.e., active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) grade II or more severe congestive heart failure, or severe arrhythmia requiring drug intervention (see Appendix 12), or a history of myocardial infarction within the last 12 months\n* Those who need immunosuppressive therapy for organ transplantation\n* Severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases\n* The baseline blood routine and biochemical indicators of the subjects did not meet the following criteria: hemoglobin ≥90g\u002FL; The absolute neutrophil count (ANC) is ≥1.5×109\u002FL; Platelet count ≥100×109\u002FL; ALT and AST≤2.5 times the normal upper limit value; ALP≤2.5 times the normal upper limit value; Serum total bilirubin \\\u003C1.5 times the normal upper limit value; Serum creatinine \\\u003C1 times the upper limit of normal; Serum albumin ≥30g\u002FL\n* Those known to have a deficiency of dihydropyrimidine dehydrogenase (DPD)\n* Those who are allergic to any investigational drug ingredients (such as irinotecan, irinotecan liposome, capecitabine, bevacizumab and camrelizumab)\n* Pregnant or breastfeeding women\n* Have received any of the following treatments:\n\nThe concomitant medication contained CYP3A4, CYP2C8 strong suppressor\u002Fstrong inducer or UGT1A1 strong suppressor within 2 weeks prior to randomization;Use immunosuppressants or systemic hormones for immunosuppressive purposes within 2 weeks before randomization (dose \\>10mg\u002F day, prednisone or other equivalent therapeutic hormones); \\\u003Cs:1\\> Received radiotherapy within 2 weeks prior to randomization;Undergo major surgeries (such as thoracotomy, laparotomy, etc.) within 4 weeks before randomization;The patient has received any other clinical study drug treatment within 4 weeks prior to randomization, unless it is an observational (non-interventional) clinical study or follow-up of an interventional clinical study.\n\n\\- Abnormal coagulation function, with a bleeding tendency, or currently undergoing thrombolytic or anticoagulant therapy. Prophylactic use of low-dose aspirin (≤100mg\u002F day) and low-molecular-weight heparin (enoxaparin 40mg\u002F day and other low-molecular-weight heparin at equivalent doses) is permitted.",{"count":499,"type":22},68,[413],"A single-arm, open-label clinical study of irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab as second-line or above treatment for patients with metastatic colorectal cancer, aiming to evaluate the efficacy and safety of irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab as second-line or above treatment for patients with metastatic colorectal cancer The medication regimen is irinotecan liposome (II) + capecitabine + bevacizumab + camrelizumab until disease progression or intolerable toxicity.",[503],"Metastatic Colorectal Cancer (CRC)",[505,506],"Metastatic colorectal cancer of stage ll or higher","The treatment regimen of irinotecan liposome combined with capecitabine and camrelizumab","2026-02-03",{"date":509,"type":39},"2026-02-09",{"date":450,"type":22},{"date":512,"type":22},"2029-02-01",{"name":45,"class":46},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":522,"briefSummary":523,"conditions":524,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":530,"leadSponsor":532,"locationsCount":4},"100621841","phase-2-investigating-the-clinical-benefits-and-underlying-mechanisms-of-danhong-injection-in-modulating-mitochondrial-homeostasis-against-sepsis-associated-myocardial-dysfunction-100621841","NCT07375862","Investigating the Clinical Benefits and Underlying Mechanisms of Danhong Injection in Modulating Mitochondrial Homeostasis Against Sepsis-Associated Myocardial Dysfunction","Inclusion Criteria:\n\n1. Patients who met the Sepsis-3 criteria, defined by a suspected or confirmed infection and an increase in the Sequential Organ Failure Assessment (SOFA) score of 2 points or more from baseline.\n2. Patients with a diagnosis of sepsis-induced myocardial dysfunction (SIMD).\n\nExclusion Criteria:\n\n1. Patients with significant primary cardiac diseases, including unstable coronary artery disease, severe cardiomyopathy, or severe valvular heart disease.\n2. Exclusion criteria included long-term use of Danhong Injection or recent use of other medication with potential significant impact on cardiac function.\n3. Patients with severe hepatic dysfunction (defined as Child-Pugh class C) or severe renal insufficiency (defined as creatinine clearance \\\u003C30 mL\u002Fmin) were excluded.\n4. Patients with a known allergy to any component of Danhong Injection or a history of severe allergic diathesis were excluded.\n5. Pregnant or lactating women\n6. Patients with severe mental illness or inability to cooperate with the study.\n7. Participation in other drug clinical trials within 3 months prior to enrollment.",{"count":521,"type":22},140,[413],"This study aims to evaluate the clinical efficacy of Danhong injection in patients with septic myocardial injury through a prospective randomized controlled trial. The study will enroll 140 patients meeting criteria for septic myocardial injury, divided into a Danhong injection group and a placebo group. Primary endpoints include changes in myocardial injury markers and improvement rates in cardiac function over 7 days, while secondary endpoints include 28-day mortality rates. This will determine whether Danhong injection possesses myocardial protective effects and provide evidence-based support for expanding its clinical indications.",[525],"Sepsis-Induced Myocardial Dysfunction","2026-01-22",{"date":528,"type":39},"2026-01-29",{"date":104,"type":22},{"date":531,"type":22},"2028-12-01",{"name":45,"class":46},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":23,"phases":540,"briefSummary":541,"conditions":542,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":4},"100621840","application-of-electrical-impedance-tomography-in-evaluating-pulmonary-function-improvement-after-high-lateral-recumbent-position-therapy-in-ards-patients-100621840","NCT07375849","Application of Electrical Impedance Tomography in Evaluating Pulmonary Function Improvement After High Lateral Recumbent Position Therapy in ARDS Patients","Inclusion Criteria:\n\n1. Age \\>= 18 years.\n2. Diagnosis of ARDS according to the Berlin Definition (2023 update).\n3. Clinically evaluated as suitable for positional therapy by physicians.\n4. Signed informed consent obtained from the patient or legal representative.\n5. Absence of severe spinal deformities or musculoskeletal disorders that may compromise safe high lateral positioning.\n6. No severe skin conditions (e.g., extensive open wounds or pressure ulcers) that may affect the feasibility of lateral positioning.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Severe cardiac diseases (e.g., unstable arrhythmia or heart failure) that may worsen with positional changes.\n3. Severe coagulation disorders with increased bleeding risk.\n4. Known allergy to the EIT device or any of its components.\n5. Severe psychiatric disorders impairing study compliance.\n6. Current participation in experimental therapies that may affect pulmonary function.\n7. Severe active infections requiring special isolation measures.\n8. Anticipated need for emergency surgery or life-threatening complications within 24 hours.",{"count":521,"type":22},[25],"This randomized controlled trial investigates the effects of prone positioning versus lateral positioning at different angles (30°, 90°, 120°) on pulmonary function improvement in patients with acute respiratory distress syndrome (ARDS). Utilizing electrical impedance tomography (EIT) technology, the study monitors key parameters including ventilation distribution and ventilation-perfusion matching in real time, while integrating respiratory mechanics and blood gas analysis data to comprehensively evaluate the therapeutic efficacy of positional adjustments. The study hypothesizes that high-angle lateral positioning may reduce adverse complications associated with prone positioning while effectively improving oxygenation and pulmonary function. The ultimate objective is to provide a safer and more personalized positional therapy regimen for clinical practice, optimizing ARDS treatment strategies to reduce mortality and enhance patient survival outcomes.",[543],"Acute Respiratory Distress Syndrome (ARDS)",{"date":528,"type":39},{"date":546,"type":22},"2026-01-01",{"date":548,"type":22},"2027-12-01",{"name":45,"class":46},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":556,"maxAge":56,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":559,"briefSummary":560,"conditions":561,"keywords":563,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":47},"100621569","a-study-on-the-effect-of-electronic-moxibustion-based-on-ziwu-liuzhu-in-treating-constipation-in-stroke-patients-100621569","NCT07372326","A Study on the Effect of Electronic Moxibustion Based on Ziwu Liuzhu in Treating Constipation in Stroke Patients","Inclusion criteria:\n\n1. Meets the diagnostic criteria of both Western medicine and traditional Chinese medicine, and has not undergone surgery or other internal medical treatments, with the occurrence of constipation;\n2. The condition is stable, without severe clinical complications;\n3. Can accept moxibustion treatment, and the local skin is undamaged;\n4. Those who agree to participate in this study and sign the informed consent form.\n\nExclusion criteria:\n\n1. Digestive tract disorders, such as intestinal polyps, tuberculosis, and tumors. Irritable bowel syndrome or constipation secondary to organic diseases (such as endocrine, metabolic or post-operative diseases); abdominal aneurysm, hepatosplenomegaly, or severe cardiovascular, liver, kidney or mental disorders and coagulation disorders.\n2. The patient had constipation before the stroke.\n3. The patient withdrew from the study due to other reasons during the course of the study.\n\nDropout criteria and termination criteria:\n\n1. Patients who have not received the prescribed treatment and whose therapeutic effect cannot be determined;\n2. Patients who experience serious adverse events or complications and are not suitable to continue the treatment and thus the trial is terminated;\n3. Patients with poor compliance, who withdraw from the treatment during the course of the trial, or who use treatment methods prohibited by this protocol concurrently, or who change the treatment method halfway on their own.\n\nNote: For any patient meeting any of the above criteria 1, they will be handled as a dropout case.","30 Years",{"count":558,"type":22},105,[25],"This study aims to explore the application effect of Ziwu Liuzhu electronic moxibustion combined with auricular points on constipation in stroke patients through clinical controlled trials, as well as the advantages over using electronic moxibustion alone.",[562],"Stroke Patients With Constipation",[564,565,566,567],"cerebral hemorrhage","constipation","midnight-midday ebb flow","electronic moxibustion","2026-01-19",{"date":570,"type":39},"2026-01-28",{"date":572,"type":39},"2025-05-15",{"date":574,"type":22},"2026-10-30",{"name":45,"class":46},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":16,"sex":17,"minAge":277,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":23,"phases":584,"briefSummary":585,"conditions":586,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":47},"100620121","mir-342-5pankg-pathway-in-early-ad-synaptic-dysfunction-100620121","NCT07353502","miR-342-5p\u002FAnkG Pathway in Early AD Synaptic Dysfunction","Effects of miR-342-5p\u002FAnkG Pathway-Mediated Axon Initial Segment Filtering Injury on Early Synaptic Dysfunction in Alzheimer's Disease and Its Clinical Applications","Inclusion Criteria:\n\nInclusion criteria for AD group:\n\n1. Meet the diagnostic criteria for \"probable AD dementia\" established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)\n2. MMSE score between 0-23 points, Clinical Dementia Rating (CDR) score ≥0.5 points, Hachinski Ischemic Score \\\u003C4 points\n3. Brain MRI showing bilateral temporal lobe and hippocampal atrophy\n4. Age ≥50 years\n\nInclusion criteria for control group:\n\n1. Healthy subjects with age matched to the AD group\n2. Normal cognitive function and good activities of daily living\n3. No dementia patients among first-degree relatives\n4. Negative brain MRI and neurological examination\n\nExclusion Criteria:\n\n1. Dementia or cognitive impairment caused by other diseases\n2. History of substance abuse\n3. Progressive primary aphasia\n4. Previous traumatic brain injury\n5. Patients with comorbid depression, schizophrenia, or severe diseases of the cardiovascular, hepatic, renal, or hematological systems\n6. Impaired consciousness and inability to cooperate\n7. Other conditions unsuitable for inclusion",{"count":151,"type":22},[25],"Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities. Current research has found that in the early stages of the disease, synaptic connections between brain nerve cells become abnormal, but the specific cause is still unclear. Investigators' previous research discovered that in the brains of diseased mice, certain special substances (the miR 342 5p\u002FAnkG-mediated pathway) might be related to this abnormality, and these substances can be detected in both blood and cerebrospinal fluid. Therefore, investigators want to further explore the specific mechanisms of abnormal nerve cell connections, seek biomarkers for early detection of the disease, and provide new ideas for early diagnosis in the future.",[284,587],"Biomarker in Early Diagnosis","2026-01-18",{"date":590,"type":39},"2026-01-20",{"date":592,"type":39},"2025-06-20",{"date":594,"type":22},"2026-03-10",{"name":45,"class":46},""]